News

CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production

CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production

Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership

Read More
Phase Four raises $26m led by New Science Ventures

Phase Four raises $26m led by New Science Ventures

Phase Four, the creator of the radio-frequency thruster for satellite propulsion, announced today that it has closed a Series B investment round of $26 million. The round was led by New Science Ventures LLC ("NSV"), a leading venture capital firm focused on building companies that leverage breakthrough science to create

Read More
Zeotap launches Predictive Audiences to empower marketers with machine learning

Zeotap launches Predictive Audiences to empower marketers with machine learning

Zeotap the leading Customer Data Platform, has today announced the launch of Predictive Audiences as part of its award-winning Customer Intelligence Platform (CIP). Designed to help marketing users increase the impact of their campaigns, it enables the creation and application of machine-learned predictive segments in just a few clicks. Predictive

Read More
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal

Read More
Zeotap builds momentum as marketing industry shifts away from cookies

Zeotap builds momentum as marketing industry shifts away from cookies

Zeotap, the Customer Intelligence Platform (CIP), has reported 126% ARR growth in 2020 among its latest milestones in growth. Building momentum from its $60.5 million Series C fundraising round last year, the company is capitalizing on the marketing industry’s move to better engage first-party data in the face of the

Read More
Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range of applications including AI/ML, 5G infrastructure, networking,

Read More
ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space raises $170m growth equity round led by T. Rowe Price funds

ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors and new investments by Fidelity Management & Research

Read More
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of VTX-958, a novel and selective allosteric TYK2 inhibitor.  In non-clinical studies, VTX-958 has shown potential to treat autoimmune diseases by

Read More
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline of immunology programs. Ventyx Biosciences combines assets from three formerly

Read More
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new research supporting ProFound AI® was presented at the European Congress of Radiology (ECR) 2021 Online meeting, taking place March 3-10, 2021. During the congress, the Company also showcased the full suite

Read More
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition Profile (FAP) 10 module has received FBI certification, the first in this category of organic photodiode (OPD) based optical sensors. The FAP 10 biometrics module is now approved for use in security applications, in

Read More
iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included

Read More